Phase 1 Trial for ALS Results of Novel Stem-Cell Therapy Presented by Neuralstem Representative

April 14, 2014

(Bio News Texas) – Neuralstem, a company that specializes in producing commercial quantities of neural stem cells of the brain and spinal cord, publicly presented the findings of their Phase 1 clinical trial involving amyotrophic lateral sclerosis (ALS) at the Keystone Symposia “Engineering Cell Fate and Function,” occurring April 6-11 in Olympic Valley, California. Results were published in Annals of Neurology in mid-March, but principal investigator Eva Feldman, PhD, MD, discussed the results of Neuralstem’s NSI-566 stem cell trial in ALS during a workshop on “Clinical Progress for Stem Cell Therapies” at the symposia.